Request to Join
has invited you to join this group
Dr. Robson graduated from the University of Virginia School of Medicine in Charlottesville, Virginia, and did his internal medicine residency and hematology oncology fellowship training at Walter Reed Army Medical Center in Washington DC. He is currently an attending physician in Clinical Genetics and Breast Cancer Medicine at the Memorial Hospital in New York and a member of the Memorial Sloan Kettering Cancer Center. He is the Clinic Director of the Clinical Genetics Service and, in that role, he oversees the clinical operations of one of the largest cancer genetic counseling services in the world. His clinical research has concentrated on the optimal application of germline information to the management of cancer patients, particularly those with breast cancer. He has also been a lead investigator for a number of trials of PARP inhibitors in patients with BRCA mutation – associated breast cancer. His current focus is on the development of new models for the acquisition of germline information, including "mainstreaming" through test ordering by primary oncology providers and broad genomic screening in the context of somatic mutational profiling. He serves on the editorial board of the Journal of Clinical Oncology and is an associate editor for the Journal of the National Cancer Institute. He is also the immediate past chair of the Ethics Committee of the American Society of Clinical Oncology and a member of the ASCO Cancer Prevention Committee and its Cancer Genetics subcommittee.
Dr. Stacy Loeb is an Assistant Professor of Urology and Population Health at New York University (NYU), specializing in prostate cancer. Dr. Loeb completed her urology residency training at Johns Hopkins and subsequently received a Masters of Science in Comparative Effectiveness Research at NYU. She has a K07 grant from the National Cancer Institute to study active surveillance for prostate cancer. Dr. Loeb is an internationally recognized expert in prostate cancer with more than 260 peer-reviewed published articles and 8 book chapters. She is on the Editorial Board for the British Journal of Urology International, European Urology, Nature Reviews Urology, Urology Practice, Reviews in Urology, and Urology Times. Dr Loeb authored the chapter on “Early Detection, Diagnosis, and Staging of Prostate Cancer” for Campbell-Walsh Urology. Dr. Loeb also frequently gives international lectures on prostate cancer, and hosts the Men’s Health Show on Sirius XM 110 US/Canada satellite radio on Wednesdays from 6-8pET. She is also an active participant in social media, and has received multiple awards from the BJU International for her contributions to social media in urology. Dr. Loeb is Chair of the American Urological Association Social Media Work Group and a member of the European Association of Urology Guidelines Office Social Media Committee. She is also Chair of the Technology and Publications Committee of the Urology Care Foundation.
I am an Associate Professor of Epidemiology at the Harvard T.H. Chan School of Public Health, Leader of Cancer Epidemiology at the Dana-Farber/Harvard Cancer Center, and a Visiting Professor at the University of Iceland. My research in cancer utilizes integrative molecular epidemiology approaches, including circulating biomarkers, inherited genetic alleles, and tumor biomarkers to study cancer risk and mortality. These projects are nested within cohorts from the US, Europe, Brazil and Australia with an emphasis in prostate cancer epidemiology. The integration of tissue biomarkers into cancer epidemiology is a relatively new area of research. I am on the Steering Committee for the Transdisciplinary Prostate Cancer Partnership (ToPCaP, www.topcapteam.org), an international, multidisciplinary effort whose objective is to integrate prostate cancer tissue biomarkers to address questions in etiology, prognosis and treatment. The projects leverages prostate cancer patients from the US and Europe, cohorts with covariate and clinical data, histopathologic and molecular pathology data, plasma and genetic biomarkers, and long-term follow-up after cancer diagnosis. The projects are undertaken in concert with the DF/HCC Prostate Cancer SPORE, for which I lead the Population Science project and an active member of the leadership team. For the past four years, I have been a faculty member for the American Association for Cancer Research Integrative Molecular Epidemiology Workshop and joined as co-director in 2016. I also co-lead the Tissue Working Group of the National Cancer Institute’s Cohort Consortium.